Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells

Nature Nanotechnology volume 17, pages 1243–1244 (2022)Cite this article

Subjects

A strategy that uses nanoconjugates to label solid cancer cells with the hematopoietic cell-specific molecule SLAMF7, broadens the scope of cancer types susceptible to immune-based anti-cancer therapies and could provide a new approach to treat solid cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Nanoconjugates to broaden the scope of solid tumour cells susceptible to macrophage-based immunotherapy.

References

  1. Wei, S. C., Duffy, C. R. & Allison, J. P. Cancer Discov. 8, 1069–1086 (2018).

    Article  Google Scholar 

  2. Feng, M. et al. Nat. Rev. Cancer 19, 568–586 (2019).

    Article  CAS  Google Scholar 

  3. Veillette, A. & Chen, J. Trends Immunol. 39, 173–184 (2018).

    Article  CAS  Google Scholar 

  4. Lu, Y. & H, K. et al. Nat. Nanotechnol. https://doi.org/10.1038/s41565-022-01245-7 (2022).

    Article  Google Scholar 

  5. Chen, J. et al. Nature 544, 493–497 (2017).

    Article  CAS  Google Scholar 

  6. Zhao, X. W. et al. Proc. of the National Academy of Sciences 108, 18342–18347 (2011).

    Article  CAS  Google Scholar 

  7. Jaiswal, S. et al. Cell 138, 271–285 (2009).

    Article  CAS  Google Scholar 

  8. Advani, R. et al. N. Engl. J. Med. 379, 1711–1721 (2018).

    Article  CAS  Google Scholar 

  9. Tang, Z. et al. Cell Rep. 37, 110111 (2021).

    Article  CAS  Google Scholar 

  10. He, Y. et al. Nat. Commun. 10, 533 (2019).

    Article  Google Scholar 

  11. Lo Russo, G. et al. Clin. Cancer Res. 25, 989–999 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Molecular Oncology, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec, Canada

    Zhenghai Tang & André Veillette

  2. Department of Medicine, University of Montréal, Montréal, Québec, Canada

    André Veillette

  3. Department of Medicine, McGill University, Montréal, Québec, Canada

    André Veillette

Authors
  1. Zhenghai Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André Veillette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to André Veillette.

Ethics declarations

Competing interests

A.V. received a contract from Bristol Myers Squibb to study the mechanism of action of anti-SLAMF7 antibody elotuzumab in multiple myeloma. He also consulted for Boehringer Ingelheim on SIRPα-CD47 blockade. The other author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, Z., Veillette, A. Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells. Nat. Nanotechnol. 17, 1243–1244 (2022). https://doi.org/10.1038/s41565-022-01244-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41565-022-01244-8

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research